Abstract
Background Recent studies identified sphingosine-1-phosphate (S1P) as an important player in immune cell trafficking and vascular dysfunction contributing to the development and progression of overt hypertension. Although targeting S1P signaling revealed therapeutic potential in different experimental hypertension studies, validations of S1P-blood pressure associations in humans are lacking.
Methods and Results In a translational approach, we explored the associations between plasma S1P, quantified using LC-MS/MS, and blood pressure in a family-based study cohort (Malmö Offspring (MOS) study; N=1026), and in a longitudinally conducted murine hypertension cohort. In MOS, linear multivariate regression analyses showed that plasma S1P associates with increased systolic blood pressure (β=1.06, P=0.015). Study subjects with systolic blood pressure ≥140 mmHg presented with significantly higher S1P plasma concentrations compared to subjects with blood pressure <120 mmHg independent of age and sex. The S1P-blood pressure association was validated in a murine model where plasma S1P increased with systolic blood pressure (r=0.7018, R2=0.4925; P<0.0001). In a sub-sample of the human study population (N=444), proteomic profiling for markers of inflammation, metabolism and cardiovascular disease was carried out using proximity Extension Assays. Testing S1P associations revealed multiple significant interactions, some of them with marked sex-specificity. Amongst them, interleukin-18, which exerts apparent vascular and immune responses during hypertension and associates to adverse cardiovascular events, strongly correlates with plasma S1P concentrations in females but not males in both humans and mice. In vitro and ex vivo validation of S1P effects on endothelial and monocytic cells of murine or human origin and resistance arteries isolated from mice disclosed augmented expression of different vascular dysfunction and inflammation markers in response to exogenously added S1P.
Conclusion Taken together, our translational findings strongly suggest a link between plasma S1P and systolic blood pressure as well as several inflammation and cardiovascular disease biomarkers in humans, encouraging further studies to investigate S1P’s potential as a therapeutic target in hypertensive disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the following funding sources: The Knut and Alice Wallenberg foundation [F 2015/2112; AM; MM]; Swedish Research Council [VR; 2017-01243; AM]; German Research Foundation [DFG; ME 4667/2-1; AM]; Ake Wibergs Stiftelse [M19-0380; AM]; Inger Bendix Stiftelse [AM-2019-10; AM] and Stohnes Stiftelse [AM]; Lund University [AJ, AM] and Region Skane [AJ; MM], Swedish Medical Research Council [MM, MOM], the Swedish Heart and Lung Foundation [MM, MOM], the Albert Pahlsson Research Foundation [MM], the Crafoord Foundation [MM], the Ernhold Lundstroms Research Foundation [MM], the Hulda and Conrad Mossfelt Foundation [MM], the Southwest Skanes Diabetes foundation [MM], the King Gustaf V and Queen Victoria Foundation [MM], the Lennart Hanssons Memorial Fund [MM], the Marianne and Marcus Wallenberg Foundation [MM], Novo Nordic Foundation (MOM and the European Research Council Consolidator grant (MOM). The Malmo Offspring Study (MOS) has been funded by the Research Council of Sweden (grant 521-2013-2756), the Heart and Lung Foundation (grant 20150427), and by funds obtained from the local Region Skane County Council (ALF) [PMN and MOM].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Regional Ethics Committee in Lund (Dnr. 2012/594).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data underlying this article are available in the article and in its online supplementary material. Study population-specific data that support the findings of this study are available upon reasonable request from the Steering Committee of Malmo Diet and Cancer study by contacting its chair, Professor Olle Melander (olle.melander{at}med.lu.se), but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available due to ethical and legal restrictions related to the Swedish Biobanks in Medical Care Act (2002:297) and the Personal Data Act (1998:204).